Open suprapubic versus retropubic prostatectomy in the treatment of benign prostatic hyperplasia during resident's learning curve: a randomized controlled trial.

PURPOSE: This study compared the suprapubic (SP) versus retropubic (RP) prostatectomy for the treatment of large prostates and evaluated perioperative surgical morbidity and improvement of urinary symptoms. MATERIALS AND METHODS: In this single centre, prospective, randomised study, 65 consecutive patients with LUTS and surgical indication with prostate volume greater than 75g underwent open prostatectomy to compare the RP (32 patients) versus SP (33 patients) technique. RESULTS: The SP group exhibited a higher incidence of complications (p=0.002). Regarding voiding pattern analysis (IPSS and flowmetry), both were significantly effective compared to pre-treatment baseline. The RP group parameters were significantly better, with higher peak urinary flow (SP: 16.77 versus RP: 23.03mL/s, p=0.008) and a trend of lower IPSS score (SP: 6.67 versus RP 4.14, p=0.06). In a subgroup evaluation of patients with prostate volumes larger than 100g, blood loss was lower in those undergoing SP prostatectomy (p=0.003). Patients with prostates smaller than 100g in the SP group exhibited a higher incidence of low grade late complications (p=0.004). CONCLUSIONS: The SP technique was related to a higher incidence of minor complications in the late postoperative period. High volume prostates were associated with increased bleeding when the RP technique was utilized. The RP prostatectomy was associated with higher peak urinary flow and a trend of a lower IPSS Score.

Open suprapubic versus retropubic prostatectomy in the treatment of benign prostatic hyperplasia during resident's learning curve: a randomized controlled trial

ABSTRACT Purpose: This study compared the suprapubic (SP) versus retropubic (RP) prostatectomy for the treatment of large prostates and evaluated perioperative surgical morbidity and improvement of urinary symptoms. Materials and Methods: In this single centre, prospective, randomised study, 65 consecutive patients with LUTS and surgical indication with prostate volume greater than 75g underwent open prostatectomy to compare the RP (32 patients) versus SP (33 patients) technique. Results: The SP group exhibited a higher incidence of complications (p=0.002). Regarding voiding pattern analysis (IPSS and flowmetry), both were significantly effective compared to pre-treatment baseline. The RP group parameters were significantly better, with higher peak urinary flow (SP: 16.77 versus RP: 23.03mL/s, p=0.008) and a trend of lower IPSS score (SP: 6.67 versus RP 4.14, p=0.06). In a subgroup evaluation of patients with prostate volumes larger than 100g, blood loss was lower in those undergoing SP prostatectomy (p=0.003). Patients with prostates smaller than 100g in the SP group exhibited a higher incidence of low grade late complications (p=0.004). Conclusions: The SP technique was related to a higher incidence of minor complications in the late postoperative period. High volume prostates were associated with increased bleeding when the RP technique was utilized. The RP prostatectomy was associated with higher peak urinary flow and a trend of a lower IPSS Score.

Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects.

OBJECTIVE: The purpose of the study was to investigate the prevalence of hyperuricemia in morbidly obese subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with metabolic syndrome abnormalities. SUBJECTS AND METHOD: We evaluated 420 morbidly obese patients. Pre and postoperative (8 months after RYGBP) blood samples were drawn. Obese patients underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of hyperuricemia was 34.28%. Hyperuricemia was more common in men than in women (51.72 vs. 29.72%; p = 0.0002). Men with hyperuricemia were more likely to have diabetes (p = 0.034) and more elevated fasting plasma glucose levels (p = 0.027). Women with hyperuricemia were more likely to have hypertension (p = 0.003), metabolic syndrome (p = 0.001), elevated triglycerides (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, uric acid levels decreased from 5.60 ± 1.28 to 4.23 ± 1.20 (p < 0.0001). The prevalence of hyperuricemia decreased from 33.6% to 6.4% (p < 0.0001), in men from 48.3% to 17.2% (p < 0.0001) and in women from 29.7% to 3.6% (p < 0.0001). CONCLUSION: Concentrations of uric acid were associated with the prevalence of metabolic abnormalities in this sample of morbidly obese patients. Also, weight loss after RYGBP can reduce uric acid levels and the prevalence of hyperuricemia.

Relation of uric acid with components of metabolic syndrome before and after Roux-en-Y gastric bypass in morbidly obese subjects / Relação do ácido úrico com os componentes da síndrome metabólica antes e após o bypass gástrico com reconstrução em Y-de-Roux em pacientes obesos mórbidos

OBJECTIVE: The purpose of the study was to investigate the prevalence of hyperuricemia in morbidly obese subjects before and after Roux-en-Y gastric bypass (RYGBP) and its relationship with metabolic syndrome abnormalities. SUBJECTS AND METHOD: We evaluated 420 morbidly obese patients. Pre and postoperative (8 months after RYGBP) blood samples were drawn. Obese patients underwent laparoscopic RYGBP and after eight months all the tests were repeated. RESULTS: The overall prevalence of hyperuricemia was 34.28 percent. Hyperuricemia was more common in men than in women (51.72 vs. 29.72 percent; p = 0.0002). Men with hyperuricemia were more likely to have diabetes (p = 0.034) and more elevated fasting plasma glucose levels (p = 0.027). Women with hyperuricemia were more likely to have hypertension (p = 0.003), metabolic syndrome (p = 0.001), elevated triglycerides (p = 0.001) and GGT (p = 0.009), and decreased HDL (p = 0.011). After surgery, uric acid levels decreased from 5.60 ± 1.28 to 4.23 ± 1.20 (p < 0.0001). The prevalence of hyperuricemia decreased from 33.6 percent to 6.4 percent (p < 0.0001), in men from 48.3 percent to 17.2 percent (p < 0.0001) and in women from 29.7 percent to 3.6 percent (p < 0.0001). CONCLUSION: Concentrations of uric acid were associated with the prevalence of metabolic abnormalities in this sample of morbidly obese patients. Also, weight loss after RYGBP can reduce uric acid levels and the prevalence of hyperuricemia.

OBJETIVO: O objetivo do estudo foi investigar a prevalência de hiperuricemia em pacientes obesos mórbidos antes e após o bypass gástrico com reconstrução em Y-de-Roux (RYGBP) e sua relação com anormalidades da síndrome metabólica. SUJEITOS E MÉTODOS: Foram avaliados 420 pacientes com obesidade mórbida. Amostras de sangue pré e pós-operatório (8 meses após RYGBP) foram obtidas. Os pacientes obesos foram submetidos a RYGBP laparoscópica e após oito meses todos os testes foram repetidos. RESULTADOS: A prevalência de hiperuricemia foi 34,28 por cento. A hiperuricemia foi mais comum em homens do que em mulheres (51,72 vs. 29,72 por cento, p = 0,0002). Homens com hiperuricemia foram mais propensos a ter diabetes (p = 0,034) e tinham níveis mais elevados de glicemia de jejum (p = 0,027). Mulheres com hiperuricemia foram mais propensas a ter hipertensão arterial (p = 0,003), síndrome metabólica (p = 0,001), triglicérides elevado (p = 0,001) e GGT (p = 0,009) e diminuição de HDL (p = 0,011). Após a cirurgia, os níveis de ácido úrico diminuíram de 5,60 ± 1,28 para 4,23 ± 1,20 (p < 0,0001). A prevalência de hiperuricemia diminuiu 33,6 por cento para 6,4 por cento (p < 0,0001), em homens de 48,3 por cento para 17,2 por cento (p < 0,0001) e nas mulheres de 29,7 por cento para 3,6 por cento (p < 0,0001). CONCLUSÃO: As concentrações de ácido úrico foram associadas com a prevalência de anormalidades metabólicas nesta amostra de pacientes com obesidade mórbida. Além disso, a perda de peso após RYGBP pode reduzir os níveis de ácido úrico e a prevalência de hiperuricemia.

Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis.

PURPOSE: HER-2/neu has been linked to the clinical progression of hormone independent prostate cancer. We performed a meta-analysis to investigate the prognostic impact of HER-2/neu over expression in patients with prostate adenocarcinoma, and its correlation with other pathological and clinical variables. MATERIALS AND METHODS: We searched the MEDLINE, Embase, CancerLit and ASCO abstract databases for published studies of HER-2/neu protein expression in primary prostate cancer tissue with a median followup of greater than 2 years and data on survival in patients with and without HER-2/neu over expression. We separately analyzed studies reporting HER-2/neu soluble receptor levels in patients with prostate cancer. RESULTS: We included 38 articles with a total of 5,976 patients. The overall RR of death in those with HER-2/neu over expression in the primary tumor was 1.63 (95% CI 1.47-1.82, p <0.0001). In the presence of over expression the recurrence RR was 1.87 (95% CI 1.59-2.21, p <0.0001). High HER-2/neu extracellular domain levels also correlated with death (RR 2.01, 95% CI 1.21-3.35, p = 0.007) and recurrence (RR 1.74, 95% CI 1.41-2.15, p <0.0001). CONCLUSIONS: There is a consistent association of HER-2/neu over expression and Gleason less than 7 with a higher RR of death and recurrence in patients with prostate cancer. Further clinical trials should test the hypothesis that HER-2/neu is a marker of a clinically worse outcome in patients with prostate cancer and a potential target for therapy.

Benefícios do exercício físico na hipertensão arterial sistêmica / Benefits of physical exercise on systemic arterial hypertension

As doenças cardiovasculares constituem a maior causade mortalidade no mundo ocidental, sendo a hipertensãoarterial, mesmo leve ou moderada, grande contribuinte paraa morbimortalidade. O tratamento da hipertensão arterialapresenta limitações, representadas pela falta de adesão comoconseqüência de diversos fatores, como: custo financeiro,efeitos colaterais dos fármacos em um paciente previamenteassintomático, falta de uma explicação adequada por parte domédico no que diz respeito às conseqüências da descontinuidadedo tratamento, baixo nível sociocultural e diversos outros. Osedentarismo é um importante fator de risco, interferindo demodo direto na morbimortalidade das doenças cardiovasculares,e indireto, devido ao seu grande papel no desenvolvimento dasíndrome metabólica e, portanto, na hipertensão arterial esuas conseqüências. Dessa forma, é de grande importância noarsenal terapêutico, proceder à implementação de modificaçõesdo estilo de vida, de preferência em forma multidisciplinar,particularmente em hipertensos menos graves. As atividadesfísicas de todos os tipos devem ser recomendadas em todosos casos, sendo este protocolo fundamentado em numerosostrabalhos sistemáticos e de metanálise, que oferecem amplorespaldo científico a este proceder. O presente estudo tem comoobjetivo avaliar o papel do exercício físico no tratamento nãofarmacológico da hipertensão arterial.

Cardiovascular diseases are the most important cause of death inthe occidental world, been the arterial hypertension, even weak ormoderate, a big contributor for morbid-mortality. Hypertensiontreatment has limitation, represented by a small adhesion ofthe treatment mainly: financial cost, no adequate explanationabout the consequences of stop the treatment, adverse effects onpreviously asymptomatic patients, low social-cultural level andothers. The sedentarism is an important risk factor, interferingdirect in the morbid-mortality of cardiovascular disease andalso due it largest influence in the metabolic syndrome andin the arterial hypertension and its consequences. Thus, it’svery important, in the treatment arsenal, the modification oflife style, particularly in cases of weak hypertension. Weak ormoderate physical activity must be recommended in all cases,like papers and met analysis defended. The present studyrevises the paper of physical exercise in the non-pharmacologicaltreatment of hypertension.